Medtronic CoreValve Evolut R U.S. Clinical Study

Aortic Stenosis Clinical Trial

Official title:

Medtronic CoreValve Evolut R United States IDE Clinical Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02207569
• Other study ID #: 10126779DOC
• Status: Completed
• Phase: N/A
• Start date: August 2014
• Est. completion date: October 28, 2020

Study information

• Verified date: October 2022
• Source: Medtronic Cardiovascular
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study objectives are to assess the safety and efficacy of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis are considered at high or extreme risk for surgical aortic valve replacement.

Description:

This objective will be accomplished by a prospective, single arm, historical controlled, multi-site study involving a minimum of 150 implanted subjects with no more than 250 implanted subjects at up to 25 study sites in the United States. Procedural and 30 day safety and efficacy results from this study will be compared to appropriate historical control data for the Medtronic CoreValve System. Subjects will be followed up to 5 years following implantation.

The enrollment phase of the study is estimated to take approximately 6-9 months. As each implanted subject is to be followed up to 5 years, the estimated study duration is approximately 66-69 months, excluding the time required for preparing the final report.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 241
• Est. completion date: October 28, 2020
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria - Severe aortic stenosis, defined as aortic valve area of < 1.0 cm2 (or aortic valve area index of < 0.6 cm2/m2) by the continuity equation, AND mean gradient > 40 mmHg or maximal aortic valve velocity > 4.0 m/sec by resting echocardiogram.

Subjects with low-flow/low gradient severe aortic stenosis can be included, provided low-dose dobutamine or exercise stress echocardiography demonstrates a mean gradient of >40 mmHg or a maximal aortic valve velocity of >4.0 m/sec, AND aortic valve area of <1.0cm2 (or aortic valve area index of <0.6 cm2/m2).

• STS score of = 8 OR documented heart team agreement of = high risk for AVR due to frailty or co-morbidities.

• Symptoms of aortic stenosis, AND NYHA Functional Class II or greater

• The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Exclusion Criteria

• Any condition considered a contraindication for placement of a bioprosthetic valve (e.g. subject is indicated for mechanical prosthetic valve).

• A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin or heparin (HIT/HITTS) and bivalirudin, ticlopidine and clopidogrel, Nitinol (titanium or nickel), contrast media

• Blood dyscrasias as defined: leukopenia (WBC < 1000 mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states.

• Untreated clinically significant coronary artery disease requiring revascularization.

• Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.

• End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min.

• Ongoing sepsis, including active endocarditis.

• Any percutaneous coronary or peripheral interventional procedure with a bare metal or drug eluting stent performed within 30 days prior to the study procedure.

• Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 10 weeks of Heart Team assessment.

• Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.

• Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA).

• Gastrointestinal (GI) bleeding that would preclude anticoagulation.

• Subject refuses a blood transfusion.

• Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).

• Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions.

• Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-ups exams.

• Currently participating in an investigational drug or another device study (excluding registries).

• Evidence of an acute myocardial infarction = 30 days before the study procedure.

• Need for emergency surgery for any reason.

• Liver failure (Child-Pugh class C).

• Subject is pregnant or breast feeding.

Anatomical exclusion criteria:

• Pre-existing prosthetic heart valve in any position.

• Mixed aortic valve disease (aortic stenosis with severe aortic regurgitation).

• Severe mitral regurgitation.

• Severe tricuspid regurgitation.

• Moderate or severe mitral stenosis.

• Hypertrophic obstructive cardiomyopathy.

• Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac mass, thrombus, or vegetation.

• Congenital bicuspid or unicuspid valve verified by echocardiography.

For transfemoral or transaxillary (subclavian) acess:

• Access vessel diameter <5.0mm or <6.0mm for patent LIMA

Related Conditions & MeSH terms

• Aortic Stenosis
• Aortic Valve Stenosis

Intervention

Device:
• CoreValve Evolut R TAVR system

Locations

Country	Name	City	State
United States	University of Michigan Health Systems	Ann Arbor	Michigan
United States	The Johns Hopkins University	Baltimore	Maryland
United States	Beth Israel Deaconcess Medical Center	Boston	Massachusetts
United States	Riverside Methodist Hospital/Ohio Health Research Institute	Columbus	Ohio
United States	Baylor Heart and Vascular Hospital	Dallas	Texas
United States	Detroit Medical Center Cardiovascular Institute	Detroit	Michigan
United States	Duke University Medical Center	Durham	North Carolina
United States	Spectrum Health	Grand Rapids	Michigan
United States	The Methodist DeBakey Heart & Vasc Ctr/The Methodist Hosp	Houston	Texas
United States	St. Vincent Heart Center of Indiana/The Care Group, LLC	Indianapolis	Indiana
United States	University of Kansas	Kansas City	Kansas
United States	University of Southern California	Los Angeles	California
United States	Aurora Health Care/St Luke's Medical Center	Milwaukee	Wisconsin
United States	Morristown Memorial Hospital	Morristown	New Jersey
United States	Yale New Haven Hospital	New Haven	Connecticut
United States	Columbia University Medical Center	New York	New York
United States	New York Langone Medical Center	New York	New York
United States	The Mount Sinai Medical Center	New York	New York
United States	Banner Good Samaritan Medical Center	Phoenix	Arizona
United States	University of Pittsburg Medical Center	Pittsburgh	Pennsylvania
United States	St. Francis Hospital	Roslyn	New York
United States	Washington Hospital Center/Medstar	Washington	District of Columbia
United States	Pinnacle Health	Wormleysburg	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Cardiovascular

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause Mortality at 30 Days by Percent	Percentage of patients that died by any cause at 30 days	Assessed at 30 days post-implantation
Primary	Percentage of Patients With Disabling Stroke at 30 Days	Stroke Diagnostic Criteria: >; Acute episode of focal or global neurological deficit with at least 2 of the following: change in level of consciousness >; hemiplegia, hemiparesis; numbness or sensory loss affecting 1 side >; dysphasia or aphasia; hemianopia; amaurosis fugax >; other neurological signs or symptoms consistent with stroke; 2.) No other readily identifiable non-stroke cause or the clinical presentation, to be determined by or in conjunctions with the designated neurologist; 3.) Confirmation of the diagnosis by at least 1 of the following: Neurological specialist >; Neuroimaging procedure, or on clincial grounds alone > Stroke: durations of neural deficit > 24 h if available neuroimaging documents a new hemofrrhage or infarct; or the neurological deficit results in death; Defined by VARC II: > An mRS (Modified Rankin Score) of 2 or more at 90 days and an increase in at least 1 mRS category from pre-stroke baseline	Assessed at 30 days post-implantation
Primary	Percent Device Success Rate Between 24 and 7 Day	Percentage of patients with Device Success defined as: Absence of procedural mortality, AND; Correct positioning of a single Evolut R valve into the proper anatomical location, AND; Absence of patient-prosthesis mismatch, and mean gradient , 20 mm Hg (or peak velocity < 3m/sec, AND; Absence of moderate or severe prosthetic valve regurgitation	Assessed at 24 hours to seven days post implantation
Primary	Percentage of Patients With Less Than Moderate Prosthetic Regurgitation at Early Post Procedure Echocardiogram (24 Hours to 7 Days)	Percentage of patience with none, trace or mild total prosthetic regurgitation at early post procedure echo cardiogram (24 hours to 7 days) as evaluated by echo core lab.	Assessed at 24 hours to 7 days post implantation
Secondary	Individual Component of VARC II Safety Endpoint: Percentage of People Requiring Valve-related Dysfunction Requiring Repeat Procedure (BAV, TAVI, or SAVR)	Percentage of patients with any valve dysfunction that requires repeat procedure (e.g. balloon valvuloplasty, TAVI, or surgical AVR), per VARC II definition.	Assessed at 30 days post-implantation
Secondary	Coronary Artery Obstruction Requiring Intervention.	Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the Evolut R prosthesis itself, the native leaflets, calcifications, or dissection, occurring during or after the TAVI procedure.	Assessed at 30 days post-implantation
Secondary	Percent VARC II Combined Safety Endpoint at 30 Days	VARC II composite safety endpoint rate includes percent freedom from the following components: All-cause mortality; All stroke (disabling and non-disabling); Life-threatening bleeding; Acute kidney injury: stage 2 or 3 (including renal replacement therapy).; Coronary artery obstruction requiring intervention.; Major vascular complication.; Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)	Assessed at 30 days post-implantation
Secondary	Percent of Patients With Acute Kidney Injury: Stage 2 or 3 (Including Renal Replacement Therapy).	Stage 2; Increase in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR; >; Urine output <0.5 mL/kg/h for >12 but <24 h > Stage 3 >; 1) Increase in serum creatinine to =300% (>3 x increase compared with baseline) OR serum creatinine of =4.0 mg/dL (=354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR; Urine output <0.3 ml/kg/h for =24 h OR; >; Anuria for =12 h	Assessed at 30 days post-implantation
Secondary	Percentage of Patients With Life-threatening or Disabling Bleeding Event Rate	Fatal bleeding (BARC type 5) OR; >; Bleeding in a critical organs, such as intracranial, intraspinal,; > intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR; >; Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR; >; Overt source of bleeding with drop in hemoglobin =5 g/dL or whole blood or packed red blood cells (RBCs) transfusion =4 units* > (BARC type 3b)	Assessed at 30 days post-implantation
Secondary	Percent Rate of Patients Who Received New Permanent Pacemaker Implant at 30 Days	Percent of patients who underwent implantation of new permanent pacemaker or ICD during or after index procedure	Assessed at 30 days
Secondary	Percent Resheath and Recapture Success Rate	Resheath or recapture success rate (where attempted) where a successful resheath is defined as the intended portion of the Evolut R is resheathed into the capsule of the delivery catheter to the intended amount, as verified by flouroscopy; and a successful recapture is defined as the entire Evolut R TAV (including the frame) is full resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip , as verified by flouroscopy. Resheath or recapture wa attempted in a subset of patients. Success rate is calculated as successful resheath or recaputure events in the number of total events. Resheath anad recapture is only possible during the index procedure.	Assessed intra-procedurally
Secondary	Hemodynamic Performance -Mean Gradient	Mean gradient by Doppler echocardiography.	Assessed at baseline, 30 days, 6 months, and 1 year
Secondary	Major Vascular Complication	Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudoaneurysm OR; >; Access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, life-threatening or major bleeding, visceral ischemia, or neurological impairment OR; >; Distal embolization (noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR; >; The use of unplanned endovascular or surgery associated with death, major bleeding, visceral ischemia or neurological impairment OR; >; Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR; >; Surgery for access site nerve injury OR; >; Permanent access related nerve injury	Assessed at 30 days post-implantation
Secondary	Hemodynamic Performance - Aortic Valve Area	Hemodynamic performance by Doppler echocardiography - Aortic Valve Area cm2	Assessed at baseline, 30 days, 6 months, and 1 year
Secondary	Hemodynamic Performance: Total Prosthetic Valve Regurgitation Graded as Moderate or Severe	Hemodynamic performance: the percent of patients who have a degree of total prosthetic valve regurgitation that is moderate or severe.	Assessed at 30 days, 6 months, and 1 year